David M Goldenberg

List of Publications by Year
in descending order

457 papers	24,417 citations	6254 80 h-index	14759 127 g-index
462 all docs	462 docs citations	462 times ranked	13210 citing authors

#	Article	IF	Citations
1	Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning. New England Journal of Medicine, 1978, 298, 1384-1388.	27.0	714
2	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	27.0	601
3	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2019, 380, 741-751.	27.0	542
4	A Novel Method of ¹⁸F Radiolabeling for PET. Journal of Nuclear Medicine, 2009, 50, 991-998.	5.0	349
5	Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy. Journal of Clinical Oncology, 2006, 24, 823-834.	1.6	327
6	Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*. Oncotarget, 2015, 6, 22496-22512.	1.8	303
7	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2141-2148.	1.6	283
8	Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research and Therapy, 2006, 8, R74.	3.5	267
9	Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2003, 21, 3051-3059.	1.6	245
10	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Antiâ€“Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. Journal of Clinical Oncology, 2006, 24, 1705-1711.	1.6	231
11	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clinical Cancer Research, 2015, 21, 3870-3878.	7.0	223
12	Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkinâ€™s Lymphoma. Clinical Cancer Research, 2004, 10, 5327-5334.	7.0	221
13	Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys. Clinical Cancer Research, 2011, 17, 3157-3169.	7.0	213
14	Epratuzumab (humanised anti-CD22 antibody) in primary SjÃ¶gren's syndrome: an open-label phase I/II study. Arthritis Research and Therapy, 2006, 8, R129.	3.5	212
15	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. Journal of Clinical Oncology, 2008, 26, 3756-3762.	1.6	211
16	Carcinoembryonic Antigen in Histopathology: Immunoperoxidase Staining of Conventional Tissue Sections2. Journal of the National Cancer Institute, 1976, 57, 11-22.	6.3	209
17	Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. Ca-A Cancer Journal for Clinicians, 2006, 56, 226-243.	329.8	207
18	Targeted therapy of cancer with radiolabeled antibodies. Journal of Nuclear Medicine, 2002, 43, 693-713.	5.0	197

#	Article	IF	Citations
19	Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6841-6846.	7.1	196
20	A Novel Facile Method of Labeling Octreotide with ¹⁸F-Fluorine. Journal of Nuclear Medicine, 2010, 51, 454-461.	5.0	193
21	Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer, 2007, 7, 2.	2.6	192
22	CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms. Clinical Cancer Research, 2007, 13, 5556s-5563s.	7.0	188
23	Inhibition of Adhesion, Invasion, and Metastasis by Antibodies Targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Research, 2005, 65, 8809-8817.	0.9	184
24	Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibodyâ€“Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjugate Chemistry, 2015, 26, 919-931.	3.6	184
25	Improved ¹⁸F Labeling of Peptides with a Fluoride-Aluminum-Chelate Complex. Bioconjugate Chemistry, 2010, 21, 1331-1340.	3.6	178
26	Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Molecular Immunology, 2007, 44, 1331-1341.	2.2	176
27	The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget, 2018, 9, 28989-29006.	1.8	169
28	Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkinâ€™s Lymphoma. Clinical Cancer Research, 2004, 10, 2868-2878.	7.0	168
29	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 5044-5051.	1.6	164
30	Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys. Clinical Cancer Research, 2005, 11, 5257-5264.	7.0	162
31	IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13408-13413.	7.1	162
32	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. Journal of Clinical Oncology, 2009, 27, 3346-3353.	1.6	154
33	In vivo hybridisation of human tumour and normal hamster cells. Nature, 1974, 250, 649-651.	27.8	153
34	Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2006, 24, 3880-3886.	1.6	148
35	Sacituzumab govitecan (IMMUâ€132), an antiâ€Tropâ€2â€SNâ€38 antibodyâ€drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer, 2017, 123, 3843-3854.	4.1	145
36	Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nature Medicine, 2005, 11, 1250-1255.	30.7	144

#	Article	IF	Citations
37	Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. Cancer, 1978, 42, 1546-1553.	4.1	143
38	CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy. Clinical Cancer Research, 2004, 10, 6606-6611.	7.0	140
39	High-Yielding Aqueous ¹⁸F-Labeling of Peptides via Al¹⁸F Chelation. Bioconjugate Chemistry, 2011, 22, 1793-1803.	3.6	137
40	Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting. Journal of Nuclear Medicine, 2008, 49, 158-163.	5.0	134
41	Monoclonal antibodies in cancer detection and therapy. American Journal of Medicine, 1993, 94, 297-312.	1.5	133
42	The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Seminars in Nuclear Medicine, 1994, 24, 142-153.	4.6	127
43	Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood, 2004, 104, 3705-3711.	1.4	126
44	Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With 131I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results. Journal of Clinical Oncology, 2005, 23, 6763-6770.	1.6	126
45	New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis. Journal of Clinical Oncology, 2006, 24, 252-258.	1.6	126
46	Sphingolipid targets in cancer therapy. Molecular Cancer Therapeutics, 2006, 5, 200-208.	4.1	125
47	Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein. Cancer, 1980, 45, 2500-2505.	4.1	122
48	Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2â€“SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical Cancer Research, 2015, 21, 5131-5138.	7.0	122
49	Therapy of Advanced Nonâ€“Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. Journal of Clinical Oncology, 2017, 35, 2790-2797.	1.6	119
50	Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy. Journal of Medicinal Chemistry, 2008, 51, 6916-6926.	6.4	115
51	Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood, 2009, 113, 1062-1070.	1.4	115
52	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology, 2013, 52, 1313-1322.	1.9	115
53	Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods. Clinical Cancer Research, 2005, 11, 7109s-7121s.	7.0	111
54	Potent and specific antitumor effects of an anti-CD22â€“targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood, 2001, 97, 528-535.	1.4	109

#	Article	IF	Citations
55	Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. Clinical Cancer Research, 2005, 11, 5215-5222.	7.0	109
56	Cancer radioimmunotherapy. Immunotherapy, 2011, 3, 349-370.	2.0	108
57	Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-Iâ€“inhibiting Antibodyâ€“Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clinical Cancer Research, 2017, 23, 5711-5719.	7.0	107
58	Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms. Gastroenterology, 1983, 84, 524-532.	1.3	106
59	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 3709-3716.	1.6	106
60	CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates. Clinical Cancer Research, 2009, 15, 6052-6061.	7.0	105
61	Milatuzumabâ€“SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics, 2013, 12, 968-978.	4.1	105
62	Durable complete responses from therapy with combined epratuzumab and rituximab. Cancer, 2008, 113, 2714-2723.	4.1	102
63	Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates. Cancer, 1997, 80, 2591-2610.	4.1	98
64	Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Research, 2013, 3, 36.	2.5	98
65	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood, 2013, 122, 3020-3029.	1.4	98
66	Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. Cancer, 1978, 42, 1546-1553.	4.1	97
67	Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Molecular Immunology, 1995, 32, 1413-1427.	2.2	96
68	Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Molecular Cancer Therapeutics, 2002, 1, 553-63.	4.1	96
69	Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer, 2002, 94, 1373-1381.	4.1	94
70	Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunology, Immunotherapy, 2003, 52, 281-296.	4.2	92
71	Synthetic Lethality Exploitation by an Antiâ€“Trop-2-SN-38 Antibodyâ€“Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2â€“wild-type Triple-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 3405-3415.	7.0	92
72	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4590-4597.	3.6	89

#	Article	IF	Citations
73	Phase I, multicentre, doseâ€escalation trial of monotherapy with milatuzumab (humanized) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Journal of Haematology, 2013, 163, 478-486.	2.5	89
74	Reâ€induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatric Blood and Cancer, 2015, 62, 1171-1175.	1.5	89
75	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. Journal of Nuclear Medicine, 2006, 47, 247-55.	5.0	88
76	GW-39: A NEW HUMAN TUMOR SERIALLY TRANSPLANTABLE IN THE GOLDEN HAMSTER. Transplantation, 1966, 4, 760-763.	1.0	86
77	Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Research and Therapy, 2010, 12, R204.	3.5	86
78	Pretargeted Molecular Imaging and Radioimmunotherapy. Theranostics, 2012, 2, 523-540.	10.0	86
79	The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Critical Reviews in Oncology/Hematology, 2001, 39, 195-201.	4.4	85
80	PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma. Clinical Cancer Research, 2007, 13, 7380-7387.	7.0	85
81	Pretargeted Immunoâ€“Positron Emission Tomography Imaging of Carcinoembryonic Antigenâ€“Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts. Molecular Cancer Therapeutics, 2010, 9, 1019-1027.	4.1	85
82	Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer, 1994, 73, 787-793.	4.1	82
83	Cancer imaging and therapy with bispecific antibody pretargeting. Update on Cancer Therapeutics, 2007, 2, 19-31.	0.4	82
84	Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. Journal of Nuclear Medicine, 2006, 47, 1678-88.	5.0	81
85	Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochemical Journal, 1996, 320, 293-300.	3.7	80
86	Sacituzumab Govitecan, a Novel Antibodyâ€“Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e75-e79.	1.9	80
87	Rapid Imaging of Infections With a Monoclonal Antibody Fragment (LeukoScan). Clinical Orthopaedics and Related Research, 1996, 329, 263-272.	1.5	80
88	Fractionated radioimmunotherapy with ⁹⁰Yâ€clivatuzumab tetraxetan and lowâ€dose gemcitabine is active in advanced pancreatic cancer. Cancer, 2012, 118, 5497-5506.	4.1	79
89	New Lyophilized Kit for Rapid Radiofluorination of Peptides. Bioconjugate Chemistry, 2012, 23, 538-547.	3.6	77
90	Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. International Journal of Cancer, 1993, 55, 938-946.	5.1	75

#	Article	IF	Citations
91	Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood, 2011, 117, 4530-4541.	1.4	75
92	A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Research, 2003, 63, 354-63.	0.9	75
93	The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7â€“3G11, is phosphorylated on serine 303. International Journal of Cancer, 1995, 62, 472-479.	5.1	74
94	Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group. Annals of Surgical Oncology, 2007, 14, 2577-2590.	1.5	74
95	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. Journal of Nuclear Medicine, 2012, 53, 1185-1192.	5.0	74
96	Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs, 2019, 11, 987-995.	5.2	74
97	Phase I/II trial of131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. , 1999, 85, 1828-1842.		73
98	Optimized labeling of NOTA-conjugated octreotide with F-18. Tumor Biology, 2012, 33, 427-434.	1.8	72
99	Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Nonâ€“Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody. Cancer Research, 2008, 68, 5282-5290.	0.9	71
100	Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunology, Immunotherapy, 1993, 37, 293-298.	4.2	70
101	Internalization and intracellular processing of an anti B-cell lymphoma monoclonal antibody, Il2. International Journal of Cancer, 1994, 56, 538-545.	5.1	70
102	Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy. Seminars in Nuclear Medicine, 2010, 40, 190-203.	4.6	70
103	A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma. Cancer Research, 2008, 68, 4819-4826.	0.9	69
104	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 3338-3346.	1.6	69
105	Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Seminars in Nuclear Medicine, 1989, 19, 332-339.	4.6	68
106	Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer, 1993, 71, 3478-3485.	4.1	68
107	The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity. Clinical Cancer Research, 2007, 13, 5586s-5591s.	7.0	68
108	Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood, 2009, 113, 6161-6171.	1.4	68

#	Article	IF	Citations
109	Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjugate Chemistry, 1992, 3, 91-99.	3.6	67
110	Imaging of colorectal carcinoma with radiolabeled antibodies. Seminars in Nuclear Medicine, 1989, 19, 262-281.	4.6	66
111	Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Molecular Cancer Therapeutics, 2007, 6, 524-531.	4.1	66
112	Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development Conference. Annals of Internal Medicine, 1981, 94, 407.	3.9	65
113	PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an ¹⁸F-Labeled Bombesin Analog. Journal of Nuclear Medicine, 2012, 53, 947-952.	5.0	65
114	Identity and nature of isolated lymphoid tumors (so-called nodal hyperplasia, hamartoma, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 studies. Cancer, 1970, 25, 1286-1300.	4.1	64
115	Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer. Cancer Research, 2004, 64, 8405-8410.	0.9	62
116	A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood, 2009, 113, 3891-3895.	1.4	62
117	Epratuzumabâ€“SN-38: A New Antibodyâ€“Drug Conjugate for the Therapy of Hematologic Malignancies. Molecular Cancer Therapeutics, 2012, 11, 224-234.	4.1	62
118	Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. Journal of Nuclear Medicine, 2003, 44, 2000-18.	5.0	62
119	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. Journal of Nuclear Medicine, 2016, 57, 1505-1511.	5.0	61
120	Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clinical Cancer Research, 2003, 9, 6567-71.	7.0	61
121	Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Molecular Biotechnology, 2007, 35, 185-197.	2.4	60
122	Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types. PPAR Research, 2008, 2008, 1-7.	2.4	60
123	Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial. Clinical Cancer Research, 2011, 17, 4091-4100.	7.0	60
124	Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. Cancer Research, 2017, 77, 5384-5394.	0.9	60
125	Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics. Cancer Research, 2008, 68, 8384-8392.	0.9	59
126	CD20-targeted tetrameric interferon-Î±, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood, 2009, 114, 3864-3871.	1.4	59

#	Article	IF	Citations
127	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2015, 14, 1079-1086.	5.8	59
128	Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft. Clinical Cancer Research, 2005, 11, 7879-7885.	7.0	58
129	Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma. Journal of Nuclear Medicine, 2009, 50, 444-453.	5.0	57
130	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opinion on Biological Therapy, 2020, 20, 871-885.	3.1	57
131	Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model. Radiology, 2008, 246, 497-507.	7.3	55
132	Altered tumor vessel maturation and proliferation in placenta growth factorâ€producing tumors: Potential relationship to postâ€therapy tumor angiogenesis and recurrence. International Journal of Cancer, 2003, 105, 158-164.	5.1	54
133	Epratuzumab in the therapy of oncological and immunological diseases. Expert Review of Anticancer Therapy, 2006, 6, 1341-1353.	2.4	54
134	Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Advanced Drug Delivery Reviews, 2008, 60, 1407-1420.	13.7	54
135	Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines. Clinical Cancer Research, 2009, 15, 2808-2817.	7.0	54
136	Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines. Molecular Cancer Research, 2009, 7, 890-896.	3.4	54
137	90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. Journal of Nuclear Medicine, 2003, 44, 77-84.	5.0	54
138	Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer, 1993, 71, 2082-2096.	4.1	53
139	Characterization of cluster 13: The epithelial/carcinoma antigen recognized by MAb RS7. International Journal of Cancer, 1994, 57, 98-102.	5.1	53
140	Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood, 2005, 106, 4308-4314.	1.4	53
141	TAp63 Regulates VLA-4 Expression and Chronic Lymphocytic Leukemia Cell Migration to the Bone Marrow in a CD74-Dependent Manner. Journal of Immunology, 2010, 184, 4761-4769.	0.8	53
142	The radiolabeling of proteins by the [18F]AlF method. Applied Radiation and Isotopes, 2012, 70, 200-204.	1.5	53
143	Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. Journal of Nuclear Medicine, 2004, 45, 1224-32.	5.0	53
144	Conjugation of phenyl isothiocyanate derivatives of carborane to antitumor antibody and in vivo localization of conjugates in nude mice. Bioconjugate Chemistry, 1991, 2, 102-110.	3.6	52

#	Article	IF	Citations
145	Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood, 2008, 111, 2211-2219.	1.4	52
146	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leukemia and Lymphoma, 2010, 51, 747-755.	1.3	52
147	Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris. JAMA Dermatology, 2014, 150, 1331.	4.1	52
148	Detection of carcinoembryonic antigen in tissue sections by immunoperoxidase. Journal of Immunological Methods, 1975, 8, 267-275.	1.4	51
149	Degranulating Eosinophils in Human Endometriosis. American Journal of Pathology, 2000, 156, 1581-1588.	3.8	51
150	The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic study. Cancer Immunology, Immunotherapy, 1991, 33, 351-358.	4.2	50
151	Development of a Streptavidinâ"Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Studies in a Human Colon Cancer Xenograft Modelâ€. Bioconjugate Chemistry, 1997, 8, 595-604.	3.6	50
152	Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood, 2006, 108, 2736-2744.	1.4	50
153	Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10â€"⁹⁰Y-IMP-288 Alone and Combined with Gemcitabine. Journal of Nuclear Medicine, 2009, 50, 2008-2016.	5.0	50
154	Phase I Radioimmunotherapy Trial with Iodine-131â€"Labeled Humanized MN-14 Antiâ€"Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal Cancer. Clinical Colorectal Cancer, 2002, 2, 31-42.	2.3	49
155	Pretargeted ¹⁷⁷Lu Radioimmunotherapy of Carcinoembryonic Antigenâ€"Expressing Human Colonic Tumors in Mice. Journal of Nuclear Medicine, 2010, 51, 1780-1787.	5.0	49
156	Efficacy of Epratuzumab, an Antiâ€<scp>CD</scp>22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	5.6	49
157	Improved iodine radiolabels for monoclonal antibody therapy. Cancer Research, 2003, 63, 111-8.	0.9	49
158	Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunology, Immunotherapy, 2005, 54, 315-327.	4.2	48
159	Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Antiâ€"Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 2276-2286.	4.1	48
160	Perspectives on cancer therapy with radiolabeled monoclonal antibodies. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 115S-27S.	5.0	48
161	Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. , 1999, 81, 985-992.		47
162	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica, 2011, 96, 567-573.	3.5	47

#	Article	IF	Citations
163	Pretargeting of Carcinoembryonic Antigenâ€“Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells. Clinical Cancer Research, 2005, 11, 7122s-7129s.	7.0	46
164	Development of humanized antibodies as cancer therapeutics. Methods, 2005, 36, 84-95.	3.8	46
165	FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood, 2011, 118, 6893-6903.	1.4	46
166	Preclinical Comparison of Al¹⁸F- and ⁶⁸Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2014, 55, 2050-2056.	5.0	46
167	Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. , 1997, 72, 477-485.		45
168	Therapeutic efficacy and dose-limiting toxicity of auger-electronvs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of125I-vs.131I-labeled CO17-1A in a human colorectal cancer model. , 1998, 76, 738-748.		45
169	Rapid diagnostic imaging of acute, nonclassic appendicitis by leukoscintigraphy with sulesomab, a technetium 99mâ€“labeled antigranulocyte antibody Fabâ€² fragment. Surgery, 1999, 125, 288-296.	1.9	45
170	Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. , 2000, 86, 276-280.		45
171	Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab). Clinical Cancer Research, 2008, 14, 6154-6160.	7.0	45
172	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica, 2008, 93, 390-397.	3.5	45
173	Detection of Early-Stage Pancreatic Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2786-2794.	2.5	45
174	Designing immunoconjugates for cancer therapy. Expert Opinion on Biological Therapy, 2012, 12, 873-890.	3.1	45
175	Improving the Therapeutic Index in Cancer Therapy by Using Antibodyâ€“Drug Conjugates Designed with a Moderately Cytotoxic Drug. Molecular Pharmaceutics, 2015, 12, 1836-1847.	4.6	45
176	Use of Carcinoembryonic Antigen Radioimmunodetection and Computed Tomography for Predicting the Resectability of Recurrent Colorectal Cancer. Annals of Surgery, 1997, 226, 621-631.	4.2	45
177	Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. , 1998, 77, 787-795.		44
178	Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel. Breast Cancer Research and Treatment, 2004, 84, 173-182.	2.5	44
179	Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models. Molecular Cancer Therapeutics, 2011, 10, 1072-1081.	4.1	44
180	Al¹⁸F labeling of peptides and proteins. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 219-223.	1.0	44

#	Article	IF	Citations
181	Therapy of B-cell malignancies by antiâ€“HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood, 2010, 115, 5180-5190.	1.4	43
182	Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood, 2012, 119, 3767-3778.	1.4	43
183	The Dock-and-Lock Method Combines Recombinant Engineering with Site-Specific Covalent Conjugation To Generate Multifunctional Structures. Bioconjugate Chemistry, 2012, 23, 309-323.	3.6	43
184	Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. Journal of Nuclear Medicine, 2004, 45, 30-9.	5.0	43
185	Internalization of an intact doxorubicin immunoconjugate. Cancer Immunology, Immunotherapy, 1994, 38, 92-98.	4.2	42
186	Breast cancer imaging with radiolabeled antibodies. Seminars in Nuclear Medicine, 1999, 29, 41-48.	4.6	42
187	Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process. , 2000, 69, 74-82.		42
188	New Antibody Conjugates in Cancer Therapy. Scientific World Journal, The, 2010, 10, 2070-2089.	2.1	42
189	A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. Journal of Nuclear Medicine, 2005, 46, 620-33.	5.0	42
190	Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). International Journal of Cancer, 1981, 27, 101-105.	5.1	41
191	Current status of cancer imaging with radiolabeled antibodies. Journal of Cancer Research and Clinical Oncology, 1987, 113, 203-208.	2.5	41
192	Comparison of therapeutic efficacy and host toxicity of two different131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. International Journal of Cancer, 1989, 44, 292-300.	5.1	41
193	Prospects of Radioimmunotherapy in Epithelial Ovarian Cancer: Results with Iodine-131-Labeled Murine and Humanized MN-14 Anti-carcinoembryonic Antigen Monoclonal Antibodies. Gynecologic Oncology, 1997, 67, 259-271.	1.4	41
194	A Bispecific Antibody-IFNÎ±2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells. Cancer Research, 2010, 70, 7600-7609.	0.9	41
195	Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1377-1383.	6.4	41
196	A pretargeting system for tumor PET imaging and radioimmunotherapy. Frontiers in Pharmacology, 2015, 6, 54.	3.5	41
197	177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nuclear Medicine and Biology, 2005, 32, 269-278.	0.6	40
198	Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood, 2010, 116, 2554-2558.	1.4	40

#	Article	IF	Citations
199	Radioimmunodetection of Prostatic Cancer. JAMA - Journal of the American Medical Association, 1983, 250, 630.	7.4	39
200	Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies. Seminars in Nuclear Medicine, 1985, 15, 2-11.	4.6	39
201	Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 777-780.	6.4	39
202	PAM4 enzyme immunoassay alone and in combination with CA 19â€9 for the detection of pancreatic adenocarcinoma. Cancer, 2013, 119, 522-528.	4.1	38
203	Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer, 1994, 73, 761-768.	4.1	37
204	Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. Molecular Imaging, 2015, 14, 7290.2015.00015.	1.4	37
205	Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. Journal of Nuclear Medicine, 2017, 58, 706-710.	5.0	37
206	Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clinical Cancer Research, 2003, 9, 3973S-81S.	7.0	37
207	Normal colonic epithelium adheres to carcinoembryonic antigen and type IV collagen. Gastroenterology, 1994, 106, 1242-1250.	1.3	36
208	Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors. Clinical Cancer Research, 2006, 12, 5587-5595.	7.0	36
209	Bispecific Antibody Pretargeting of Radionuclides for Immunoâ€“Single-Photon Emission Computed Tomography and Immunoâ€“Positron Emission Tomography Molecular Imaging: An Update. Clinical Cancer Research, 2007, 13, 5577s-5585s.	7.0	36
210	Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood, 2010, 116, 3258-3267.	1.4	36
211	Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. International Journal of Cancer, 2012, 131, 49-58.	5.1	36
212	Imaging integrin alphaâ€vâ€betaâ€3 expression in tumors with an ¹⁸Fâ€labeled dimeric RGD peptide. Contrast Media and Molecular Imaging, 2013, 8, 238-245.	0.8	36
213	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematology,the, 2015, 2, e108-e117.	4.6	36
214	Development of a Streptavidinâ^'Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Reagent Developmentâ€. Bioconjugate Chemistry, 1997, 8, 585-594.	3.6	35
215	Perspectives on oncologic imaging with radiolabeled antibodies. Cancer, 1997, 80, 2431-2435.	4.1	35
216	Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents: A New Generation of Therapeutics. Leukemia and Lymphoma, 2002, 43, 953-959.	1.3	35

#	Article	IF	Citations
217	Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies. Technology in Cancer Research and Treatment, 2005, 4, 375-391.	1.9	35
218	A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2â€“Expressing Epithelial Cancers. Journal of Nuclear Medicine, 2012, 53, 1625-1632.	5.0	35
219	SPECT- and Fluorescence Imageâ€“Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigenâ€“Targeting Antibody. Journal of Nuclear Medicine, 2014, 55, 1519-1524.	5.0	35
220	Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. Journal of Nuclear Medicine, 2003, 44, 67-76.	5.0	35
221	Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clinical Cancer Research, 2003, 9, 3897S-913S.	7.0	35
222	Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer, 2000, 88, 333-343.	4.1	34
223	Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. International Journal of Cancer, 2003, 106, 965-972.	5.1	34
224	Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies. Clinical Cancer Research, 2013, 19, 347-356.	7.0	34
225	A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. MAbs, 2014, 6, 381-391.	5.2	34
226	Î±- Versus Î²-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigenâ€“Expressing Human Colon Cancer Xenografts. Journal of Nuclear Medicine, 2017, 58, 926-933.	5.0	34
227	Epratuzumab: targeting B-cell malignancies through CD22. Clinical Cancer Research, 2003, 9, 3991S-4S.	7.0	34
228	Radioimmunotherapy of Solid Tumors: A Review "Of Mice and Men". Hybridoma, 1997, 16, 101-107.	0.6	33
229	Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radioiodinated Peptides Containing<scp>d</scp>-Amino Acids. Bioconjugate Chemistry, 1999, 10, 231-240.	3.6	33
230	Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Critical Reviews in Oncology/Hematology, 2001, 39, 147-154.	4.4	33
231	Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer, 2010, 116, 1093-1100.	4.1	33
232	Preclinical studies on targeted delivery of multiple IFNÎ±2b to HLA-DR in diverse hematologic cancers. Blood, 2011, 118, 1877-1884.	1.4	33
233	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1593-602.	6.4	33
234	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematology,the, 2017, 4, e35-e45.	4.6	33

#	Article	IF	Citations
235	Siteâ€specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. International Journal of Cancer, 1988, 41, 832-839.	5.1	32
236	Radioimmunotherapy of non-Hodgkinâ€™s lymphoma: a critical appraisal. Expert Review of Clinical Immunology, 2005, 1, 47-62.	3.0	32
237	Advances in Radioimmunotherapy in the Age of Molecular Engineering and Pretargeting. Cancer Investigation, 2006, 24, 82-97.	1.3	31
238	The combination of milatuzumab, a humanized antiâ€CD74 antibody, and veltuzumab, a humanized antiâ€CD20 antibody, demonstrates activity in patients with relapsed and refractory Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2015, 169, 701-710.	2.5	31
239	Selection of a dtpa chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. International Journal of Cancer, 1990, 46, 79-85.	5.1	30
240	Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma. Cancer, 2002, 94, 51-61.	4.1	30
241	Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates. Nuclear Medicine and Biology, 2005, 32, 513-519.	0.6	30
242	The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Research and Therapy, 2012, 14, R54.	3.5	30
243	Combining ABCG2 Inhibitors with IMMU-132, an Antiâ€“Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Molecular Cancer Therapeutics, 2016, 15, 1910-1919.	4.1	30
244	Repeated adjuvant antiâ€CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and longâ€term efficacy results of a prospective phase 2 study. Cancer, 2017, 123, 638-649.	4.1	30
245	Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clinical Cancer Research, 2003, 9, 3886S-96S.	7.0	30
246	Immunoperoxidase detection of carcinoembryonic antigen.An overview. Cancer, 1978, 42, 1540-1545.	4.1	29
247	Improved Targeting of Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 3552-3561.	7.0	29
248	Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody. Journal of Nuclear Medicine, 2011, 52, 1601-1607.	5.0	29
249	Horizontal transmission of malignancy by cellâ€“cell fusion. Expert Opinion on Biological Therapy, 2012, 12, S133-S139.	3.1	29
250	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Frontiers in Medicine, 2015, 2, 84.	2.6	29
251	Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opinion on Biological Therapy, 2016, 16, 883-893.	3.1	29
252	Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer, 1997, 80, 2636-2641.	4.1	28

#	Article	IF	Citations
253	Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival?11Dr Goldenberg is a member of the board of Immunomedics and a shareholder. Immunomedics markets CEA-Scan (arcitumomab).. Journal of the American College of Surgeons, 2000, 191, 511-518.	0.5	28
254	Pretargeting: taking an alternate route for localizing radionuclides. Tumor Biology, 2012, 33, 591-600.	1.8	28
255	Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2Ã—Anti-HSG Bispecific Antibody and a ¹⁷⁷Lu-Labeled Peptide. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 323-329.	1.0	28
256	Targeting CD22 as a strategy for treating systemic autoimmune diseases. Therapeutics and Clinical Risk Management, 2007, 3, 953-9.	2.0	28
257	Synthesis of Carcinoembryonic Antigen in vitro. Nature: New Biology, 1972, 239, 189-190.	4.5	27
258	Lymphoma imaging with a new technetium-99m labelled antibody, LL2. European Journal of Nuclear Medicine and Molecular Imaging, 1992, 19, 394-401.	2.1	27
259	Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotype antibody in tumor-bearing nude mice. International Journal of Cancer, 1992, 51, 266-273.	5.1	27
260	Sphingomyelin Potentiates Chemotherapy of Human Cancer Xenografts. Biochemical and Biophysical Research Communications, 2000, 268, 603-606.	2.1	27
261	CD22-directed monoclonal antibody therapy for lymphoma. Seminars in Oncology, 2003, 30, 457-464.	2.2	27
262	Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer, 2013, 13, 170.	2.6	27
263	Microheterogeneity of a purified IgG1, due to asymmetric fab glycosylation. Molecular Immunology, 1992, 29, 751-758.	2.2	26
264	Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. International Journal of Cancer, 1995, 61, 557-566.	5.1	26
265	90Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy:Â Radiolabeling and Animal Biodistribution Studiesâ€. Bioconjugate Chemistry, 1998, 9, 773-782.	3.6	26
266	Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using ¹²⁴I-IMP-R4â€“Labeled Antibody ch806. Journal of Nuclear Medicine, 2010, 51, 967-972.	5.0	26
267	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica, 2015, 100, e128-e131.	3.5	26
268	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. European Journal of Cancer, 2015, 51, 1857-1864.	2.8	26
269	Radioimmunodetection of colorectal cancer. Cancer, 1980, 45, 1243-1247.	4.1	25
270	Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 525-533.	1.0	25

#	Article	IF	Citations
271	Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2153-2164.	6.4	25
272	Lowâ€dose antiâ€‹scp›CD‹/scp›20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. British Journal of Haematology, 2013, 162, 693-701.	2.5	25
273	Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Molecular Cancer, 2013, 12, 143.	19.2	25
274	Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer. Cancer Research, 2014, 74, 6216-6223.	0.9	25
275	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica, 2014, 99, 1738-1745.	3.5	25
276	Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus. PLoS ONE, 2014, 9, e98315.	2.5	24
277	Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibodyâ€“Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). Molecular Cancer Therapeutics, 2018, 17, 196-203.	4.1	24
278	Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotype antibody. International Journal of Cancer, 1994, 56, 580-584.	5.1	23
279	Antibody protein dose and radioimmunodetection of gw-39 human colon tumor xenografts. International Journal of Cancer, 1987, 39, 611-617.	5.1	22
280	The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. , 1997, 71, 429-435.		22
281	Optimization of Hapten-Peptide Labeling for Pretargeted ImmunoPET of Bispecific Antibody Using Generator-Produced ‹sup›68‹/sup›Ga. Journal of Nuclear Medicine, 2011, 52, 555-559.	5.0	22
282	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Research, 2012, 2, 5.	2.5	22
283	Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties. Bioconjugate Chemistry, 2013, 24, 63-71.	3.6	22
284	Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer. Molecular Cancer, 2014, 13, 53.	19.2	22
285	Differentiation of Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis by PAM4 Immunohistochemistry. Archives of Pathology and Laboratory Medicine, 2014, 138, 220-228.	2.5	22
286	Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. Journal of Nuclear Medicine, 2020, 61, 1205-1211.	5.0	22
287	Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget, 2020, 11, 3849-3862.	1.8	22
288	A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Molecular Cancer Therapeutics, 2004, 3, 1559-64.	4.1	22

#	Article	IF	Citations
289	Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clinical Cancer Research, 2005, 11, 777-86.	7.0	22
290	Chemotherapy of two morphologically similar human tumors growing in the cheek pouch of the golden hamster: H. Ad. No. 1 and GW-39. European Journal of Cancer, 1967, 3, 95-101.	0.9	21
291	Characterization and localization of carcinoembryonic antigen in a squamous cell carcinoma of the cervix. Gynecologic Oncology, 1976, 4, 204-211.	1.4	21
292	Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2. , 1996, 78, 157-168.		21
293	Improving the treatment of nonâ€Hodgkin lymphoma with antibodyâ€targeted radionuclides. Cancer, 2010, 116, 1134-1145.	4.1	21
294	Phase I clinical evaluation of a new murine monoclonal antibody (mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer, 1994, 73, 864-877.	4.1	20
295	Carcinoembryonic Antigen as a Target Cancer Antigen for Radiolabeled Antibodies: Prospects for Cancer Imaging and Therapy. Tumor Biology, 1995, 16, 62-73.	1.8	20
296	Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(abâ€²)2 antibody. Cancer, 2010, 116, 1111-1117.	4.1	20
297	IMMU-140, a Novel SN-38 Antibodyâ€“Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. Molecular Cancer Therapeutics, 2018, 17, 150-160.	4.1	20
298	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. Frontiers in Medicine, 2019, 6, 124.	2.6	20
299	Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. Cancer Immunology, Immunotherapy, 1992, 35, 127-134.	4.2	19
300	Carcinoembryonic Antigen as a Target for Radioimmunotherapy of Human Medullary Thyroid Carcinoma: Antibody Processing, Targeting, and Experimental Therapy with 131I and 90Y Labeled MAbs. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 37-47.	1.0	19
301	Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody. Clinical Cancer Research, 2005, 11, 2727-2734.	7.0	19
302	A New Method to Produce MonoPEGylated Dimeric Cytokines Shown with Human Interferon-Î±2b. Bioconjugate Chemistry, 2009, 20, 1899-1907.	3.6	19
303	Novel strategies for improved cancer vaccines. Expert Review of Vaccines, 2009, 8, 567-576.	4.4	19
304	Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer, 2010, 116, 1118-1125.	4.1	19
305	Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 1-12.	1.0	19
306	Using antibodies to target cancer therapeutics. Expert Opinion on Biological Therapy, 2012, 12, 1173-1190.	3.1	19

#	Article	IF	Citations
307	<scp>BCR</scp>â€<scp>ABL</scp>1 molecular remission after ⁹⁰<scp>Y</scp>â€epratuzumab tetraxetan radioimmunotherapy in <scp>CD</scp>22⁺<scp>P</scp>h⁺<scp>B</scp>â€<scp>ALL</scp>: proof of principle. European Journal of Haematology, 2013, 91, 552-556.	2.2	19
308	Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2â€"Bispecific Antibody Is Enhanced in Combination with Interferon-Î±. Molecular Cancer Therapeutics, 2014, 13, 2341-2351.	4.1	19
309	Immunoperoxidase detection of carcinoembryonic antigen.An overview. Cancer, 1978, 42, 1540-1545.	4.1	19
310	Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 2015, 6, 4274-4285.	1.8	19
311	Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clinical Cancer Research, 2002, 8, 1213-22.	7.0	19
312	Current perspectives and challenges in the use of monoclonal antibodies as imaging and therapeutic agents. Advanced Drug Delivery Reviews, 1990, 4, 279-318.	13.7	18
313	Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunology, Immunotherapy, 1991, 32, 303-310.	4.2	18
314	Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates. Journal of Immunological Methods, 1998, 213, 131-144.	1.4	18
315	Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. International Journal of Cancer, 2001, 94, 564-571.	5.1	18
316	Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74. Nuclear Medicine and Biology, 2003, 30, 715-723.	0.6	18
317	Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 901-909.	6.4	18
318	Horizontal Transmission of Malignancy: In-Vivo Fusion of Human Lymphomas with Hamster Stroma Produces Tumors Retaining Human Genes and Lymphoid Pathology. PLoS ONE, 2013, 8, e55324.	2.5	18
319	In vivo proliferation of heterotransplanted human cancer cells. European Journal of Cancer, 1967, 3, 315-319.	0.9	17
320	Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. Critical Reviews in Oncology/Hematology, 2001, 39, 79-86.	4.4	17
321	Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. MAbs, 2015, 7, 199-211.	5.2	17
322	Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts. Molecular Imaging and Biology, 2015, 17, 94-101.	2.6	17
323	A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model. International Journal of Cancer, 1990, 46, 1101-1106.	5.1	16
324	Prospects for the Management of Non-Small-Cell Carcinoma of the Lung with Monoclonal Antibodies. Chest, 1991, 99, 1466-1476.	0.8	16

#	Article	IF	Citations
325	SPECT Anti-CEA Monoclonal Antibody Detection of Occult Colorectal Carcinoma Metastases. Clinical Nuclear Medicine, 1991, 16, 849-852.	1.3	16
326	Comparative biodistribution and radioimmunotherapy of monoclonal antibody rs7 and its f(abâ€²)2 in nude mice bearing human tumor xenografts. Cancer, 1994, 73, 816-823.	4.1	16
327	Changes in Tumor Vascular Permeability in Response to Experimental Radioimmunotherapy: A Comparative Study of 11 Xenografts. Tumor Biology, 1997, 18, 367-377.	1.8	16
328	Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. Aids, 2006, 20, 1911-1915.	2.2	16
329	Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leukemia and Lymphoma, 2011, 52, 273-284.	1.3	16
330	Radiopharmaceutical therapy in the era of precision medicine. European Journal of Cancer, 2014, 50, 2360-2363.	2.8	16
331	Colon-specific antigen-p (CSAp). I: Initial clinical evaluation as a marker for colorectal cancer. Cancer, 1982, 50, 919-926.	4.1	15
332	Anin vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. International Journal of Cancer, 2004, 108, 293-300.	5.1	15
333	Pretargeting of Carcinoembryonic Antigenâ€“Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen Ã— Anti-Indiumâ€“Labeled Diethylenetriaminepentaacetic Acid Antibody. Clinical Cancer Research, 2005, 11, 7130s-7136s.	7.0	15
334	Complex and defined biostructures with the dock-and-lock method. Trends in Pharmacological Sciences, 2012, 33, 474-481.	8.7	15
335	A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro. PLoS ONE, 2012, 7, e41235.	2.5	15
336	Prevention of Acute Graft-versus-Host Disease in a Xenogeneic SCID Mouse Model by the Humanized Anti-CD74 Antagonistic Antibody Milatuzumab. Biology of Blood and Marrow Transplantation, 2013, 19, 28-39.	2.0	15
337	In-Vivo Fusion of Human Cancer and Hamster Stromal Cells Permanently Transduces and Transcribes Human DNA. PLoS ONE, 2014, 9, e107927.	2.5	15
338	CD74 interferes with the expression of fas receptor on the surface of lymphoma cells. Journal of Experimental and Clinical Cancer Research, 2014, 33, 80.	8.6	15
339	Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. Gynecologic Oncology Reports, 2018, 25, 37-40.	0.6	15
340	Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. International Journal of Clinical and Experimental Pathology, 2010, 4, 1-12.	0.5	15
341	Novel radioimmunopharmaceuticals for cancer imaging and therapy. Current Opinion in Investigational Drugs, 2008, 9, 1302-16.	2.3	15
342	Altered metabolism of carcinoembryonic antigen in hamsters bearing GW-39 tumours. Nature, 1974, 249, 837-838.	27.8	14

#	Article	IF	Citations
343	Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope. International Journal of Cancer, 1990, 46, 310-314.	5.1	14
344	Physiological factors influencing radioantibody uptake: A study of four human colonic carcinomas. International Journal of Cancer, 1992, 51, 935-941.	5.1	14
345	Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site. International Journal of Cancer, 1995, 60, 534-538.	5.1	14
346	Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer, 2000, 89, 104-115.	4.1	14
347	Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). Tumor Biology, 2012, 33, 601-606.	1.8	14
348	18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1501-1510.	6.4	14
349	Clinical Studies of Prostatic Cancer Imaging with Radiolabeled Antibodies Against Prostatic Acid Phosphatase. Urologic Clinics of North America, 1984, 11, 277-281.	1.8	14
350	Purification and Characterization of Carcinoembryonic Antigen from GW-39, a Xenografted Human Colonic Tumor System. Tumor Biology, 1988, 9, 212-220.	1.8	13
351	Cytokine Intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF. Cancer, 1994, 73, 1083-1092.	4.1	13
352	Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer, 1997, 80, 2660-2666.	4.1	13
353	Advances in the use of monoclonal antibodies in cancer radiotherapy. Pharmaceutical Science & Technology Today, 2000, 3, 90-98.	0.7	13
354	Advances and challenges in developing cytokine fusion proteins as improved therapeutics. Expert Opinion on Drug Discovery, 2009, 4, 181-194.	5.0	13
355	In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (67/68Ga)-labeled haptens by pretargeting. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 141-50.	1.0	13
356	Retention of Human Properties by a Xenografted Human Colonic Tumor, GW-77, Propagated in Unconditioned Hamsters. Experimental Biology and Medicine, 1970, 135, 657-659.	2.4	12
357	Introduction to the international conference on the clinical uses of carcinoembryonic antigen. Cancer, 1978, 42, 1397-1398.	4.1	12
358	Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabeled antigranulocyte antibody imaging agent. Journal of Pediatric Surgery, 2004, 39, 1338-1344.	1.6	12
359	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. Journal of Nuclear Medicine, 2012, 53, 1926-1932.	5.0	12
360	Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*. Leukemia and Lymphoma, 2016, 57, 803-811.	1.3	12

#	Article	IF	Citations
361	Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. Journal of Nuclear Medicine, 2021, 62, 1221-1227.	5.0	12
362	Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT. Oncotarget, 2018, 9, 27502-27513.	1.8	12
363	Suppression of Tumor Vascular Activity by Radioantibody Therapy: Implications for Multiple Cycle Treatments. Selective Cancer Therapeutics, 1991, 7, 9-16.	0.5	11
364	Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90â€“Labeled Anti-CD22 Monoclonal Antibody. Clinical Lymphoma and Myeloma, 2003, 4, 56-59.	2.1	11
365	A new mammalian host cell with enhanced survival enables completely serumâ€free development of highâ€level protein production cell lines. Biotechnology Progress, 2011, 27, 766-775.	2.6	11
366	Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). Annals of the Rheumatic Diseases, 2021, 80, 954-955.	0.9	11
367	Colon-specific antigen-p (CSAp). II: Further characterization in colorectal and pancreatic cancer. Cancer, 1982, 50, 927-931.	4.1	10
368	Haematological effects of radioimmunotherapy in cancer patients. British Journal of Haematology, 1992, 80, 69-76.	2.5	10
369	Can occult metastases be Treated by radioimmunotherapy?. Cancer, 1997, 80, 2656-2659.	4.1	10
370	Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine. Critical Reviews in Oncology/Hematology, 2001, 39, 173-180.	4.4	10
371	Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1249-1258.	6.4	10
372	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Physics, 2015, 2, 5.	2.7	10
373	Cancer Imaging with Radiolabeled Antibodies. Frontiers of Radiation Therapy and Oncology, 1990, 24, 90-95.	1.4	9
374	Comparison of IgG and F(abâ€²)2 fragments of bispecific anti-RCCÃ—anti-DTIn-1 antibody for pretargeting purposes. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1089-1095.	6.4	9
375	Induction of Apoptosis by Cross-Linking Antibodies Bound to Human B-Lymphoma Cells: Expression of Annexin V Binding Sites on the Antibody Cap. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 185-193.	1.0	9
376	Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer. Hospital Practice (1995), 2010, 38, 82-93.	1.0	9
377	Al18F Labeling of Affibody Molecules. Journal of Nuclear Medicine, 2014, 55, 1043.1-1043.	5.0	9
378	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. Haematologica, 2016, 101, 1327-1332.	3.5	9

#	Article	IF	Citations
379	Antigens Associated with Human Solid Tumors. , 1980, , 329-369.		9
380	In-vivo antibody imaging for the detection of human tumors. Cancer Treatment and Research, 1990, 51, 273-292.	0.5	9
381	Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. International Journal of Oncology, 2002, 20, 379-84.	3.3	9
382	Synergistic effects of X-rays and drugs on a human tumor xenograft, GW-39. European Journal of Cancer, 1970, 6, 73-80.	0.9	8
383	Stathmokinetic effect of colcemid on a presumptive human-hamster hybrid tumor, GW-478. Experimental and Molecular Pathology, 1971, 14, 134-137.	2.1	8
384	Karyology of a human colonic carcinoma (GW-39) serially xenografted in hamsters and in nude mice. Cancer Letters, 1977, 2, 195-200.	7.2	8
385	Effects of methotrexate-carcinoembryonic-antigen-antibody immunoconjugates on GW-39 human tumors in nude mice. Cancer Immunology, Immunotherapy, 1990, 31, 197-201.	4.2	8
386	Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Immunology, Immunotherapy, 2006, 55, 47-55.	4.2	8
387	Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time. Journal of Clinical Oncology, 2012, 30, 2165-2165.	1.6	8
388	Interferon-Î»1 Linked to a Stabilized Dimer of Fab Potently Enhances both Antitumor and Antiviral Activities in Targeted Cells. PLoS ONE, 2013, 8, e63940.	2.5	8
389	Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. Biomedicines, 2020, 8, 548.	3.2	8
390	Anti-antibody enhancement of tumor imaging. Cancer Treatment and Research, 1990, 51, 433-455.	0.5	8
391	Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines. PLoS ONE, 2012, 7, e44235.	2.5	8
392	Oncogenesis by interspecific interaction of malignant murine and non-malignant hamster cellsin vitro. International Journal of Cancer, 1975, 15, 282-300.	5.1	7
393	Immunoperoxidase Localization of Carcinoembryonic Antigen in Normal Human Intestinal Mucosa<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>. Journal of the National Cancer Institute, 1981, , .	6.3	7
394	Chimerization of mu-9. Cancer, 1997, 80, 2667-2674.	4.1	7
395	Factors influencing hematologic toxicity of radioimmunotherapy with131I-labeled anti-carcinoembryonic antigen antibodies. Cancer, 1997, 80, 2749-2753.	4.1	7
396	Use of Galactosylated-Streptavidin as a Clearing Agent with111In-Labeled, Biotinylated Antibodies to Enhance Tumor/Non-Tumor Localization Ratios. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 307-316.	1.0	7

#	Article	IF	Citations
397	Labeling of anti-tumor antibodies and antibody fragments with Tc-99m. Cancer Treatment and Research, 1990, 51, 233-244.	0.5	7
398	Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies. Cancer Research, 2014, 74, CT211-CT211.	0.9	7
399	Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results.. Blood, 2006, 108, 2719-2719.	1.4	7
400	Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models. EJNMMI Research, 2019, 9, 108.	2.5	7
401	Preliminary findings in the evaluation of hepatic malignancies by radioimmunodetection, X-ray computed tomography, and magnetic resonance imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1986, 12, 429-435.	2.1	6
402	Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1992, 19, 87-99.	0.3	6
403	Al¹⁸F: A New Standard for Radiofluorination. Journal of Nuclear Medicine, 2013, 54, 1170.1-1170.	5.0	6
404	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. Haematologica, 2017, 102, e184-e186.	3.5	6
405	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2017, 2017, 2141-2148.	1.6	6
406	Clinical Utility of Radioimmunoscintigraphy of Non-Hodgkin's Lymphoma with Radiolabelled LL2 Monoclonal Antibody., Lymphoscanâ„¢: Preliminary Results. Tumori, 1995, 81, 173-178.	1.1	5
407	Thiolations, 99mTc Labelings, and Animal In Vivo Biodistributions of Divalent Monoclonal Antibody Fragments. Bioconjugate Chemistry, 1996, 7, 290-297.	3.6	5
408	Application of cytokine intervention for improved radio-antibody dose delivery. , 1997, 72, 166-173.		5
409	Recent progress in cancer therapy with radiolabeled monoclonal antibodies. Therapeutic Delivery, 2011, 2, 675-679.	2.2	5
410	Abstract CT206: SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results. Cancer Research, 2014, 74, CT206-CT206.	0.9	5
411	Alteration in tryptic peptide patterns of ferritins purified from human colon carcinoma. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1979, 581, 193-197.	1.7	4
412	Tumor targeting and pharmacokinetics of unmodified and modified F(ab)2 fragments of an anti-CEA murine monoclonal antibody (Immu-14). Nuclear Medicine and Biology, 1995, 22, 425-435.	0.6	4
413	Defining the optimal spacing between repeat radioantibody doses in experimental models. Cancer, 1997, 80, 2624-2635.	4.1	4
414	Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice. , 1997, 70, 323-329.		4

#	Article	IF	Citations
415	Co-Secretion of Two Distinct Kappa Light Chains by the Mu-9 Hybridoma. Hybridoma, 1999, 18, 325-333.	0.6	4
416	Unique molecular markers in human endometriosis: implications for diagnosis and therapy. Expert Reviews in Molecular Medicine, 2001, 3, 1-12.	3.9	4
417	B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: Comment on the editorial by St.Clair and Tedder. Arthritis and Rheumatism, 2006, 54, 2344-2344.	6.7	4
418	The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes. Antibodies, 2013, 2, 353-370.	2.5	4
419	Experimental model systems for antibody targeting and radioimmunodetection. Cancer Treatment and Research, 1990, 51, 29-52.	0.5	4
420	Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results. Cancer Research, 2015, 75, CT236-CT236.	0.9	4
421	A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer. EJNMMI Research, 2019, 9, 86.	2.5	4
422	Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.. Journal of Clinical Oncology, 2014, 32, 3107-3107.	1.6	4
423	Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).. Journal of Clinical Oncology, 2016, 34, 8559-8559.	1.6	4
424	Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).. Journal of Clinical Oncology, 2016, 34, 9011-9011.	1.6	4
425	Radioactive antibodies: Selective targeting and treatment of cancer and other diseases. , 0, , 10-29.		4
426	Labeling of monoclonal antibody conjugates with 90Y. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1991, 42, 421-426.	0.5	3
427	Monoclonal antibodies targeting CD20. MAbs, 2013, 5, 335-336.	5.2	3
428	Cancer Imaging and Therapy with Radiolabeled Antibodies. Advances in Experimental Medicine and Biology, 1991, 303, 107-117.	1.6	3
429	Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552). Cancer Research, 2015, 75, P5-19-27-P5-19-27.	0.9	3
430	Enhancing the antitumor potency of T cells redirected by bispecifc antibodies. Oncoscience, 2017, 4, 120-121.	2.2	3
431	A Divalent Hapten-Peptide Induces Apoptosis in Human Nonâ€“Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 Ã— Anti-Hapten Bispecific Antibodies. Clinical Cancer Research, 2007, 13, 5564s-5571s.	7.0	2
432	Some like it hot: lymphoma radioimmunotherapy. Blood, 2009, 113, 4823-4824.	1.4	2

#	Article	IF	Citations
433	New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma. Expert Opinion on Emerging Drugs, 2010, 15, 569-583.	2.4	2
434	Antibody-Targeted Therapeutic Radionuclides in the Management of Colorectal Cancer. , 2013, , 207-237.		2
435	Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity.. Blood, 2006, 108, 2495-2495.	1.4	2
436	Antimarker antibodies for the external imaging of gastrointestinal cancer. Cancer Treatment and Research, 1984, , 351-362.	0.5	2
437	Radioactive antibodies for cancer detection in vivo. Clinical Immunology Newsletter, 1982, 3, 61-64.	0.1	1
438	Representation of Epitopes on Colon-Specific Antigen-p Defined by Monoclonal Antibodies<xref ref-type="fn" rid="FN2">2</xref>. Journal of the National Cancer Institute, 1987, , .	6.3	1
439	CEA Immunoscintigraphy Detects Resectable Rectal Cancer Recurrence and Improves Survival. Coloproctology, 2000, 22, 23-28.	0.3	1
440	Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. Medical Radiology, 2012, , 551-556.	0.1	1
441	Clinical radioimmunodetection: The second decade. Cancer Treatment and Research, 1990, 51, 3-9.	0.5	1
442	Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody.. Blood, 2004, 104, 3289-3289.	1.4	1
443	Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2007, 110, 3419-3419.	1.4	1
444	Immunoconjugate Anticancer Therapeutics. , 2010, , 371-392.		1
445	Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results. Cancer Research, 2015, 75, P5-19-08-P5-19-08.	0.9	1
446	Novel Peptide Camptothecin Drug-linkers for Potent ADCsâ€”Letter. Molecular Cancer Therapeutics, 2022, 21, 237-237.	4.1	1
447	Endobronchial Deposition of Radioactive Monoclonal Antibody in Patients with Inoperable Non-Small-Cell Carcinoma of the Lung. Chest, 1992, 102, 1633-1634.	0.8	0
448	Introduction to the supplement, â€œCancer Therapy with Antibodies and Immunoconjugatesâ€• Cancer, 2010, 116, 1011-1012.	4.1	0
449	Medullary Thyroid Carcinoma. Medical Radiology, 2012, , 315-321.	0.1	0
450	Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies. Medical Radiology, 2012, , 607-615.	0.1	0

#	Article	IF	Citations
451	Antibodies for Nuclear Medicine Therapy. Medical Radiology, 2012, , 125-138.	0.1	0
452	Introduction to this special issue on tumor targeting. Tumor Biology, 2012, 33, 571-572.	1.8	0
453	Medullary Thyroid Carcinoma. , 2013, , 155-163.		0
454	Radioimmunotherapy of Pancreatic Adenocarcinoma. , 2013, , 239-255.		0
455	Pretargeting: Advancing the Delivery of Radionuclides. , 2013, , 369-381.		0
456	Preface: Special Issue on Tumor-Stromal Crosstalk in Oncogenesis. Critical Reviews in Oncogenesis, 2013, 18, v-vii.	0.4	0
457	Tumor pO2 Assessments in Human Xenograft Tumors Measured by EPR Oximetry: Location of Paramagnetic Materials. Advances in Experimental Medicine and Biology, 2003, 530, 205-214.	1.6	0